AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses
Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
Researchers are evaluating the safety of allogeneic Adipose Derived Mesenchymal Stem Cells
(AMSC) use during hemodialysis arteriovenous fistula and arterial bypass creation and its
efficacy on improving access maturation and primary anastomotic patency.